Is Orforglipron Generic? Generic Name vs. Brand Name

No — orforglipron does not currently have a generic version. “Orforglipron” is actually the nonproprietary (generic) name of the drug itself, while “Foundayo” is the brand name it’s sold under, and right now Foundayo is the only version on the market. The confusion is understandable: unlike a brand name such as Ozempic, “orforglipron” already sounds like a chemical or generic term — which leads a lot of people to search for a cheaper “generic orforglipron” that doesn’t yet exist.

Why does “orforglipron” sound like a generic name?

Because it is one, just not in the way most people mean when they say “generic drug.” Every prescription medication has two names:

• A nonproprietary name — the name for the active ingredient itself, used on the FDA-approved label, in medical literature, and by prescribers and pharmacists. This is what “orforglipron” is.
• A brand name — the manufacturer’s marketed product name. This is what “Foundayo” is: Eli Lilly’s brand name for orforglipron tablets.

That two-name pattern is standard across drugs, including other GLP-1 medications. “Semaglutide” is the nonproprietary name for the active ingredient sold under three different brand names — Ozempic, Wegovy, and Rybelsus — depending on form and approved use, per MedlinePlus drug information. “Tirzepatide” is the nonproprietary name sold as Mounjaro and Zepbound. Orforglipron follows the same pattern: one nonproprietary name, one brand name (so far).

Is a “generic orforglipron” available to buy?

No. What most people actually mean by “generic” is a separate, typically lower-cost version of a drug — made by a different manufacturer, approved by the FDA as bioequivalent to the brand — that a pharmacist can substitute for the brand-name product. That kind of generic does not exist for orforglipron right now. Foundayo, per its FDA-approved label, is the only version of orforglipron currently available.

How does this compare to other GLP-1 medications?

None of the major GLP-1 receptor agonists on the market today have a substitutable generic version, whether they’re pills or injections:

Nonproprietary (generic) name	Brand name(s)	Form	Generic version available?
Orforglipron	Foundayo	Oral tablet	No
Semaglutide	Ozempic, Wegovy	Injection	No
Semaglutide	Rybelsus	Oral tablet	No
Tirzepatide	Mounjaro, Zepbound	Injection	No

Sources: FOUNDAYO FDA label (DailyMed) and the MedlinePlus semaglutide and tirzepatide drug information pages, linked below.

This is normal for the GLP-1 category as it currently stands — these are all relatively recent medications, and none of them has yet reached the point in its life cycle where a generic competitor has entered the market. If you’re comparing orforglipron to these other options more broadly, orforglipron vs Ozempic and orforglipron vs tirzepatide cover the mechanism and administration differences in depth, and our Foundayo (orforglipron) guide is a good starting point if you’re new to the medication. For more on orforglipron’s approval status itself, see is orforglipron FDA-approved.

When might a generic orforglipron show up?

This article won’t guess at a date. In general, a newly approved brand-name drug is protected from generic competition for a period of time by patents and regulatory exclusivity, and it typically takes years before another manufacturer can bring an FDA-approved generic version to market — if one is ultimately filed and approved at all. A generic manufacturer has to file its own application with the FDA and demonstrate that its version is bioequivalent to the brand before it can be sold as a substitute; that process doesn’t start until the brand’s protections have expired or been successfully challenged. Nothing in orforglipron’s FDA-approved label or in the sources cited here specifies when, or whether, that will happen for this drug. If cost is your main concern right now, the more useful question isn’t “when will a generic exist” but “what are my actual options today” — covered in our orforglipron price and does insurance cover orforglipron guides.

Does the FDA approval itself say anything about generics?

Orforglipron’s FDA-approved label, available on DailyMed, describes the approved medication — its indication, dosing, and safety information — under both its nonproprietary name (orforglipron) and its brand name (Foundayo). It doesn’t reference a generic competitor, because none has been approved. That’s consistent with how drug labels work generally: a label describes the specific approved product, and a new generic entry would come with its own separate FDA approval and its own labeling, not an amendment to Foundayo’s existing one.

Don’t confuse “generic” with “compounded”

One place this gets genuinely confusing: compounded versions of GLP-1 medications have circulated as lower-cost alternatives, and it’s easy to assume a compounded product is functionally the same as a generic. It isn’t. A generic drug goes through FDA review and is confirmed bioequivalent to the brand it copies. A compounded product is prepared by a compounding pharmacy on a different regulatory basis and is not an FDA-approved generic equivalent of orforglipron or any other GLP-1 medication. If you’re weighing that distinction, compounded vs. orforglipron walks through what compounding actually means and how it differs from both the brand and a true generic.

Bottom line

“Orforglipron” is the generic (nonproprietary) name of the active ingredient — not a separate, cheaper product you can currently buy. Foundayo is the only branded version on the market, and no FDA-approved generic orforglipron tablet exists today, the same way none currently exists for semaglutide or tirzepatide either. That may change over time as these medications age in the market, but there’s no confirmed timeline for it. For now, your real cost and coverage questions are best answered by looking at Foundayo’s actual current pricing and your insurance plan’s formulary — not by waiting on a generic that isn’t here yet.